Loading…
The response to Immune Checkpoint Inhibitors (ICIs) Therapy in cancer is currently predicted by different individual parameters – with varying degrees of accuracy: tumor mutation burden, tumor-infiltering T cell density, dendritic cell frequencies, and expression of checkpoint ligands.